JPND will support research on Personalised Medicine for Neurodegenerative Diseases

The EU Joint Programme - Neurodegenerative Disease Research (JPND) has chosen to focus on the area of Precision Medicine, which relates to the targeting of specific elements responsible for pathology in a given individual at a particular point in time. It is an emerging approach for disease prevention, diagnosis and treatment that takes into account individual variability in genes, biological/molecular characteristics together with environmental and lifestyle factors.

Neurodegenerative diseases are characterised by a large variability in their origins, mechanisms and clinical expression. One of the greatest challenges for treating neurodegenerative diseases is the deciphering of this variability. The EU Joint Programme - Neurodegenerative Disease Research (JPND) will therefore shortly launch a call for "Multinational research projects on Personalised Medicine for Neurodegenerative Diseases". More than EUR 30 million has already been earmarked by JPND member countries and the European Commission for this action.

The call will focus on Precision Medicine in the following research areas:

  • Diagnosis (e.g. biomarkers, imaging data, omics approaches, big data analyses)
  • Prevention (e.g. biomarkers for studying novel treatments and interventions, co-morbidities, digital technologies, stratification within cohort studies and clinical trials)
  • Care (e.g. improvement of social and health care systems, molecular profiling, imaging, lifestyle data)

 The following neurodegenerative diseases will be included in the call:

  • Alzheimer’s disease and other dementias
  • Parkinson’s disease and PD‐related disorders
  • Prion diseases
  • Motor neuron diseases
  • Huntington’s disease
  • Spinocerebellar ataxia (SCA)
  • Spinal muscular atrophy (SMA)

The call is expected to be launched in early January 2019, and submission of pre-proposals will probably close in March 2019.

For more information, please visit the JPND website

Posted by

Share: